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Abstract: Ureaplasma species are common colonizers of the adult genitourinary tract and often
considered as low-virulence commensals. Intraamniotic Ureaplasma infections, however, facilitate
chorioamnionitis and preterm birth, and cases of Ureaplasma-induced neonatal sepsis, pneumonia,
and meningitis raise a growing awareness of their clinical relevance. In vitro studies are scarce
but demonstrate distinct Ureaplasma-driven impacts on immune mechanisms. The current study
addressed cytokine and chemokine responses upon exposure of native or lipopolysaccharide (LPS)
co-stimulated human brain microvascular endothelial cells (HBMEC) to Ureaplasma urealyticum
or U. parvum, using qRT-PCR, RNA sequencing, multi-analyte immunoassay, and flow cytometry.
Ureaplasma exposure in native HBMEC reduced monocyte chemoattractant protein (MCP)-3 mRNA
expression (p < 0.01, vs. broth). In co-stimulated HBMEC, Ureaplasma spp. attenuated LPS-evoked
mRNA responses for C-X-C chemokine ligand 5, MCP-1, and MCP-3 (p < 0.05, vs. LPS) and
mitigated LPS-driven interleukin (IL)-1α protein secretion, as well as IL-8 mRNA and protein
responses (p < 0.05). Furthermore, Ureaplasma isolates increased C-X-C chemokine receptor 4 mRNA
levels in native and LPS co-stimulated HBMEC (p < 0.05). The presented results may imply
immunomodulatory capacities of Ureaplasma spp. which may ultimately promote chronic colonization
and long-term neuroinflammation.
Keywords: Ureaplasma urealyticum; Ureaplasma parvum; neuroinflammation; meningitis; blood–brain
barrier; HBMEC
1. Introduction
Ureaplasma urealyticum and U. parvum represent some of the smallest self-replicating pathogens
and are generally considered as commensals, given their common colonization of the adult
genitourinary tract [1]. Nonetheless, maternal–fetal transmission seems to occur frequently, and
intraamniotic Ureaplasma infection may significantly contribute to chorioamnionitis and preterm
birth [2–4]. The clinical relevance of a postnatal Ureaplasma infection, however, is still the subject of
discussion and controversy [5]. Ureaplasma species were found responsible for invasive infections
in immunocompromised adults and may furthermore cause pneumonia, sepsis, and meningitis in
preterm and term neonates, with highest risk at low gestational ages [5–12]. Neonatal meningitis
and neuroinflammation may provoke profound brain injury, possibly having long-term health
implications [13–15]. Intraventricular hemorrhage (IVH) and white matter disease, both relevant
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neurological morbidities of prematurity, have been associated with inflammation [16–18]. Some studies
even described an association between IVH and Ureaplasma colonization in preterm infants [19,20].
Considering these severe sequelae as well as reported Ureaplasma detection rates of up to 20% in the
cord blood and/or cerebrospinal fluid (CSF) of preterm infants, it is likely that Ureaplasma spp. have to
be regarded as being of considerable clinical relevance [2,5,20]. Nonetheless, clinical and in vitro data
addressing Ureaplasma-driven neuroinflammation and underlying pathomechanisms are limited.
Inflammation is a condition carefully balanced by numerous mediators. These include
pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1α, IL-1β, and
IL-6; the anti-inflammatory cytokines IL-1 receptor antagonist (RA) and IL-10; the chemokine IL-8;
monocyte chemoattractant proteins (MCP); and C-X-C chemokine ligands (CXCL) and receptors
(CXCR) [21]. Matrix metalloproteinases (MMP) contribute to chemotaxis and degrade membranes [22].
Within the brain, inflammatory mediators are expressed primarily by residential macrophages such
as microglia, but also by astrocytes and oligodendrocytes, as well as vascular endothelial cells [21].
Particularly noteworthy in neuroinflammation is the blood–brain barrier (BBB), which is responsible
for maintaining the homeostasis of the central nervous system (CNS) and regulates the entry of
macromolecules, microbes, and immune cells into the brain [23,24]. Compromised integrity of the BBB
is common to many neuroinflammatory morbidities [23,24].
We recently established a cell culture model of Ureaplasma meningitis, using human brain
microvascular endothelial cells (HBMEC) as integral components of the BBB. For the first time, we could
provide in vitro evidence of Ureaplasma-induced apoptosis and barrier impairment in HBMEC [25,26].
Subsequently, the current study assessed Ureaplasma-driven cytokine and chemokine responses in native
and, to mimic co-infections, Escherichia coli lipopolysaccharide (LPS)-primed HBMEC. To account
for regulation of immune responses at the levels of transcription and translation, we correlated
Ureaplasma-induced mRNA and protein expression for relevant inflammatory mediators using
quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR), RNA sequencing,
multi-analyte immunoassay, and flow cytometry (Supplementary file 1).
2. Results
2.1. Pro-inflammatory Cytokine and Chemokine Responses in HBMEC upon Stimulation with Ureaplasma
Isolates or LPS
Ureaplasma stimulation of HBMEC for 30 h resulted in decreased MCP-3 mRNA expression
(qRT-PCR: U. urealyticum serovar 8 (Uu8) 0.34-fold ± 0.30, p = 0.0381; U. parvum serovar 3 (Up3)
0.21-fold ± 0.13, p = 0.0008, vs. control), an effect that remained significant when compared to a broth
control (Figure 1d). The broth itself moderately induced MCP-3 (Figure 1d,e). Ureaplasma-driven
MCP-3 mRNA results were not reflected by altered protein secretion when analyzed at 24 and 48 h
(Figure 1f).
Stimulation of native HBMEC with Ureaplasma isolates did not evoke significant mRNA or protein
responses for IL-1α, MCP-1, CXCL5, or IL-8 (Figure 1), and furthermore, Ureaplasma stimulation did not
have any impact on mRNA or protein expression of IL-1β, IL-6, or TNF-α (data not shown). MMP-9
mRNA and protein were not expressed in native HBMEC, nor did we observe any Ureaplasma-induced
increases (data not shown).
LPS, on the other hand, induced distinct mRNA and protein responses for most given mediators
(Figure 1). Compared to control cells, LPS-stimulated HBMEC showed higher IL-1α mRNA (p < 0.01)
and protein (p < 0.001) levels (Figure 1a–c), elevated MCP-3 mRNA (p < 0.01) and protein (p < 0.001)
expression (Figure 1d–f), increased MCP-1 mRNA (p < 0.001) and protein (p < 0.05) levels (Figure 1g–i),
a higher abundance of CXCL5 mRNA (p < 0.05, vs. control) and protein (p < 0.01) (Figure 1j–l), and
increased IL-8 mRNA and protein expression (p < 0.01; Figure 1m–p). IL-1β mRNA, IL-6 mRNA, and
secreted protein, as well as TNF-α mRNA and secreted protein, were also significantly increased by
LPS stimulation of HBMEC (data not shown). MMP-9 mRNA and protein were not inducible by LPS
(data not shown).
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Figure 1. Cytokine and chemokine expression in HBMEC exposed to Ureaplasma spp. or LPS. qRT-
PCR (a, d, g, j, m), RNA sequencing (b, e, h, k, n), and multi-analyte immunoassay (c, f, i, l, o) were 
applied for determination of quantitative mRNA expression and protein secretion. Intracellular IL-8 
was additionally quantified by flow cytometry (p). Data are presented as means ± SD and were 
obtained from n ≥ 3 independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001 vs. unstimulated 
control; ° p < 0.05, °° p < 0.01, °°° p < 0.001 vs. broth; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. LPS). CXCL: 
C-X-C chemokine ligand; HBMEC: human brain microvascular endothelial cells; IL: interleukin; LPS: 
lipopolysaccharide; MCP: monocyte chemoattractant protein; RPKM: reads per kilo base per million 
mapped reads; SD: standard deviation; Up3: Ureaplasma parvum serovar 3; Uu8: Ureaplasma 
urealyticum serovar 8. 
2.2. Pro-inflammatory Cytokine and Chemokine Responses in Co-stimulated HBMEC 
Whereas Ureaplasma spp. did not evoke distinct responses for most cytokines and chemokines 
in native HBMEC (Figure 1), we observed a significant impact on cells co-stimulated with LPS. Both 
Ureaplasma isolates significantly down-regulated LPS-induced IL-1α protein secretion after 48 h 
(Uu8+LPS 0.26-fold ± 0.11, p = 0.0169, vs. LPS; Uu8+LPS 0.21-fold ± 0.09, p = 0.0076, vs. broth+LPS; 
Up3+LPS 0.22-fold ± 0.10, p = 0.0122, vs. LPS; Up3+LPS 0.18-fold ± 0.08, p = 0.0080, vs. broth+LPS; 
Figure 1. Cytokine and chemokine expression in HBMEC exposed to Ureaplasma spp. or LPS. qRT-PCR
(a, d, g, j, m), RNA sequencing (b, e, h, k, n), and multi-analyte immunoassay (c, f, i, l, o) were applied
for determination of quantitative mRNA expression and protein secretion. Intracellular IL-8 was
additionally quantified by flow cytometry (p). Data are presented as means ± SD and were obtained
from n ≥ 3 independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001 vs. unstimulated control;
◦ p < 0.05, ◦◦ p < 0.01, ◦◦◦ p < 0.001 vs. broth; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. LPS). CXCL:
C-X-C chemokine ligand; HBMEC: human brain microvascular endothelial cells; IL: interleukin; LPS:
lipopolysaccharide; MCP: monocyte chemoattractant protein; RPKM: reads per kilo base per million
mapped reads; SD: standard deviation; Up3: Ureaplasma parvum serovar 3; Uu8: Ureaplasma urealyticum
serovar 8.
2.2. Pro-inflammatory Cytokine and Chemokine Responses in Co-stimulated HBMEC
Whereas Ureaplasma spp. did not evoke distinct responses for most cytokines and chemokines
in native HBMEC (Figure 1), we observed a significant impact on cells co-stimulated with LPS.
Both Ureapl ma isolates significantly down-regulated LPS-i duced IL-1α protei secretion after 48 h
(Uu8+LPS 0.26-fold ± 0.11, p = 0.0169, s. LPS; Uu8+LPS 0.21-f ld ± 0.09, p = 0.0076, vs. broth+LPS;
p3+LPS 0.22-fold ± 0.10, p = 0.0122, vs. LPS; Up3+LPS 0.18-fold ± 0.08, p = 0.0080, vs. broth+LPS;
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Figure 2c), although we did not observe distinct Ureaplasma-driven mRNA effects in co-stimulated
HBMEC (Figure 2a,b). Ureaplasma spp. attenuated MCP-3 mRNA responses in LPS-stimulated HBMEC
(qRT-PCR: Uu8+LPS 0.08-fold ± 0.06, p = 0.0251, vs. LPS; Uu8+LPS 0.04-fold ± 0.03, p = 0.0299, vs.
broth+LPS; Up3+LPS 0.17-fold ± 0.08, p = 0.0131, vs. LPS; Up3+LPS 0.09-fold ± 0.04, p = 0.0292, vs.
broth+LPS; Figure 2d,e). The abundance of secreted MCP-3 protein was also reduced in co-stimulated
cells; however, it did reach statistical significance (Figure 2f). Furthermore, LPS-evoked MCP-1 mRNA
levels were mitigated upon Ureaplasma exposure (qRT-PCR: Uu8+LPS 0.35-fold ± 0.08, p = 0.0397, vs.
LPS; Uu8+LPS 0.28-fold ± 0.07, p = 0.0181, vs. broth+LPS; Up3+LPS 0.48-fold ± 0.3, p = 0.0132, vs.
LPS; Up3+LPS 0.40-fold ± 0.25, p = 0.0002, vs. broth+LPS; Figure 2g,h). Broth effects were mainly
responsible for an increase in MCP-1 protein secretion in co-stimulated cells (Figure 2i). Both Ureaplasma
isolates significantly mitigated LPS-induced CXCL5 mRNA responses after 30 h (qRT-PCR: Uu8+LPS
0.30-fold ± 0.10, p = 0.0309, vs. LPS; Uu8+LPS 0.29-fold ± 0.10, p = 0.0174, vs. broth+LPS; Up3+LPS
0.35-fold ± 0.11, p = 0.0274, vs. LPS; Up3+LPS 0.34-fold ± 0.11, p = 0.0167, vs. broth+LPS; Figure 2j,k).
Co-stimulated HBMEC also showed a trend towards reduced CXCL5 protein secretion (Figure 2l).
LPS-induced IL-8 mRNA levels were reduced upon 30 h of Uu8 exposure in HBMEC (qRT-PCR:
Uu8+LPS 0.49-fold ± 0.20, p = 0.0276, vs. LPS; Uu8+LPS 0.37-fold ± 0.15, p = 0.0059, vs. broth+LPS;
Figure 2m,n). Although the abundance of secreted IL-8 protein was not influenced (Figure 2o),
both Ureaplasma isolates significantly down-regulated LPS-driven intracellular IL-8 protein responses
after 24 h (Uu8+LPS 0.26-fold ± 0.16, p = 0.0068, vs. LPS; Uu8+LPS 0.20-fold ± 0.12, p < 0.0001, vs.
broth+LPS; Up3+LPS 0.42-fold ± 0.20, p = 0.0434, vs. LPS; Up3+LPS 0.32-fold ± 0.15, p = 0.0012, vs.
broth+LPS; Figure 2p) and 48 h (Uu8+LPS 0.08-fold ± 0.21, p = 0.0130, vs. LPS; Uu8+LPS 0.04-fold ±
0.11, p < 0.0001, vs. broth+LPS; Up3+LPS 0.01-fold ± 0.03, p = 0.0255, vs. LPS; Up3+LPS 0.006-fold ±
0.02, p = 0.0001, vs. broth+LPS; Figure 2p). Ureaplasma spp. did not affect LPS-evoked effects regarding
IL-1β, IL-6, TNF-α, or MMP-9 (data not shown).
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additionally quantified by flow cytometry (p). Data are presented as means ± SD and were obtained 
from n ≥ 3 individual experiments (# p < 0.05, ## p < 0.01 vs. LPS; § p < 0.05, §§ p < 0.01, §§§ p < 0.001 
vs. broth+LPS). CXCL: C-X-C chemokine ligand; HBMEC: human brain microvascular endothelial 
cells; IL: interleukin; LPS: lipopolysaccharide; MCP: monocyte chemoattractant protein; RPKM: reads 
per kilo base per million mapped reads; SD: standard deviation; Up3: Ureaplasma parvum serovar 3; 
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2.3. Anti-inflammatory Cytokine Responses in Mono- and Co-stimulated HBMEC 
Anti-inflammatory IL-1RA and IL-10 showed neither relevant basal expression in HBMEC nor 
induction on mRNA or protein levels upon exposure to Ureaplasma or LPS or by co-stimulation with 
Ureaplasma isolates and LPS (data not shown). 
2.4. CXCR4 Responses in Mono- and Co-stimulated HBMEC 
Figure 2. Cytokine and chemokine expression in HBMEC co-stimulated with Ureaplasma spp. and
LPS. Expressi n of mRNA and protein secretio were determined using qRT-PCR (a, d, g, j, m),
RNA sequenci g (b, e, h, k, n), and multi-analyte immunoassay (c, f, i, l, o). Intracellular IL-8 was
additionally quantified by flow cytometry (p). Data are pre ented as means ± SD nd were obtained
from n ≥ 3 individual experiments (# p < 0.05, ## p < 0.01 vs. LPS; § p < 0.05, §§ p < 0.01, §§§ p < 0.001
vs. broth+LPS). CXCL: C-X-C chemokine ligand; HBMEC: human brain microvascular endothelial
cells; IL: interleukin; PS: lipopolysaccharide; MCP: monocyte chemoattractant protein; RPKM: reads
p r kilo bas per million map ed reads; SD: standard deviation; Up3: Ureaplasma parvum serovar 3;
Uu8: Ureaplasma urea yticum serovar 8.
2.3. Anti-inflammatory Cytokine Responses in Mono- and Co-stimulated HBMEC
Anti-infla matory IL-1RA and IL-10 sh wed either relevant basal expression in HBMEC nor
induction on mRNA or protein levels upon exposure to Ureaplasma or LPS or by co-stimulation with
Ureaplasma isolates and LPS (data not shown).
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2.4. CXCR4 Responses in Mono- and Co-stimulated HBMEC
We observed significantly increased CXCR4 mRNA levels in HBMEC exposed to Ureaplasma
isolates for 30 h (qRT-PCR: Uu8 3.3-fold ± 0.8, p = 0.0144; Up3 3.1-fold ± 0.6, p = 0.0083, vs. broth;
Figure 3a,b). LPS stimulation similarly enhanced CXCR4 mRNA expression in HBMEC (p < 0.01, vs.
control; Figure 3a,b). In HBMEC co-stimulated with LPS, Up3 significantly enhanced CXCR4 mRNA
levels after a 30 h stimulation period (RNA-seq: Up3+LPS 2.3-fold ± 0.2, p = 0.0322, vs. LPS; 2.7-fold ±
0.2, p = 0.0092, vs. broth+LPS; Figure 3d).
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Figure 3. CXCR4 responses in mono- and co-stimulated HBMEC. CXCR4 mRNA levels in
mono-stimulated cells were assessed by qRT-PCR (a) and RNA sequencing (b). In co-stimulated
HBMEC, qRT-PCR (c) and RNA sequencing (d) were used to determine CXCR4 mRNA levels. Data are
presented as means ± SD and were obtained from n ≥ 3 independent experiments (* p < 0.05, ** p < 0.01
vs. unstimulated control; ◦ p < 0.05, ◦◦ p < 0.01, ◦◦◦ p < 0.001 vs. broth; # p < 0.05 vs. LPS; § p < 0.05,
§§ p < 0.01 vs. broth+LPS). CXCR: C-X-C chemokine receptor; HBMEC: human brain microvascular
endothelial cells; LPS: lipopolysaccharide; RPKM: reads per kilo base per million mapped reads; SD:
standard deviation; Up3: Ureaplasma parvum serovar 3; Uu8: Ureaplasma urealyticum serovar 8.
3. Discussion
Inflammation is a fastidiously balanced condition orchestrated by cytokines, chemokines, and
their respective receptor [27]. Although a number of ase eports suggest a profound clinical
rel vance of Ur aplasma spp. in neonatal neuroinflammation [11,12], we are only beginning to unrave
the underlying pathomechanisms. For the first ti e, this study provides i sights i to meticulous
Ureaplasma-driven cytokine and chemokine responses n HBMEC. Our results dem nstrate that
differential modulations of immune defense m cha isms rather than fierce direct pro-inflamma ion
initiat Ureaplasma-induced neuroinflammation.
Whe s LPS, wi ely used to mimic bacterial infections in vitro, evoked distinct pro-inflammatory
responses in HBMEC, expressed by mRNA and protein incr ases for CXCL5 IL-1α, IL-1β, IL-6, IL-8,
MCP-1, MCP-3, and TNF-α, Ureaplasma spp. failed to induce similar effects (Figure 1). MCP-3 mRNA
levels were even down-regulated upon 30 h of Ureaplasma stimulation (Fig re 1d).
Int. J. Mol. Sci. 2019, 20, 3583 7 of 15
Chemokines such as CXCL5, IL-8, MCP-1, and MCP-3 are essential for leukocyte recruitment,
and cytokines like IL-1α, IL-1β, IL-6, and TNF-α function as intracellular messengers promoting
inflammatory responses, with IL-1α particularly initiating cytokine responses and neutrophil influx
to sites of inflammation [28,29]. An increase of these pro-inflammatory mediators is a physiological
phenomenon in infections and necessary for a sufficient immune defense. A lack thereof, as seen
in Ureaplasma-stimulated cells, may impede pathogen elimination and facilitate chronic Ureaplasma
infections. Interestingly, our in vitro results are underlined by a clinical study demonstrating that
Ureaplasma detection within the CSF of preterm infants of <1500 g birth weight was not associated
with increased CSF IL-1β, IL-6, and TNF-α levels [20].
Ureaplasma spp. not only failed to evoke pro-inflammatory cytokine and chemokine responses
in native HBMEC but furthermore modulated LPS-evoked immune reactions in co-stimulated cells
(Table 1). We observed distinct Ureaplasma-driven attenuation of LPS-induced CXCL5, IL-1α, IL-8,
MCP-1, and MCP-3 responses (Figure 2). These findings in co-stimulated cells might reflect deficient
immune responses to secondary pathogens in vivo. Ureaplasma spp. may thus increase the susceptibility
of the CNS to additional infections. Underlining our in vitro findings, animal models demonstrated
mitigation of LPS-induced immune responses in chronic Ureaplasma-colonized fetal sheep [30], and a
higher risk for neonatal sepsis was described in Ureaplasma-colonized preterm infants [31].
Table 1. Effects of Ureaplasma spp. on LPS-evoked cytokine and chemokine responses and potential
in vivo relevance. Ureaplasma spp. modulated LPS-induced cytokine and chemokine responses.
Impacts were either antagonistic (LPS effects reduced) or additive (LPS effects enhanced). Significantly
modulated readout parameters are listed for each mediator as well as the potential clinical relevance
of modulated responses. BBB: blood–brain barrier; CXCL: C-X-C chemokine ligand; CXCR: C-X-C
chemokine receptor; IL: interleukin; LPS: lipopolysaccharide; MCP: monocyte chemoattractant protein.
↑: increased.
LPS Effect LPS + Ureaplasma spp. Potential In Vivo Relevance
CXCL5 mRNA and protein ↑ antagonistic (mRNA) reduced immune responses
CXCR4 mRNA ↑ additive (mRNA) compromised BBB integrity
IL-1α mRNA and protein ↑ antagonistic (protein) reduced immune responses
IL-8 mRNA and protein ↑ antagonistic (mRNA, protein) reduced immune responses
MCP-1 mRNA and protein ↑ antagonistic (mRNA) reduced immune responses
MCP-3 mRNA and protein ↑ antagonistic (mRNA) reduced immune responses
Furthermore, chemokines are no longer considered only as pro-inflammatory mediators but
are also known to exert protective and regenerative effects in the CNS [24]. MCP-1, for example, is
necessary for recruitment of monocytes and macrophages into the CNS not only in inflammation
but also under physiological conditions [24]. MCP-1 is expressed in human fetal brains [32], and
up-regulated MCP-1 was found to increase the tolerance for brain ischemia in mice [33]. MCP-1 may
thus have a neuroprotective function. Down-regulation of LPS-induced MCP-1 and other chemokine
responses by Ureaplasma spp., as observed in this study (Figure 2), may therefore indicate decreased
resilience of the CNS against secondary inflammatory or non-infectious impacts in vivo, facilitating
subsequent brain injury. This may not only explain the potential association of Ureaplasma spp. with
IVH [19,20]. Given, for example, the influence of ischemia on the development of white matter disease
in preterm infants [18], Ureaplasma-driven reduced CNS resilience may causally contribute to several
other neurological morbidities of prematurity.
Our results moreover demonstrate a relevant increase of CXCR4 mRNA expression in HBMEC
upon Ureaplasma exposure, the extent of which is comparable to effects evoked by LPS (Figure 3a,b).
CXCR4 is a G-protein-coupled seven-transmembrane receptor expressed by B and T cells, monocytes,
and endothelial cells [34,35]. It mediates inflammatory cell migration and contributes to physiological
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neurodevelopmental processes, but it was furthermore found to be increased in viral encephalitis and
autoimmune neuroinflammation [35–37]. Accordingly, CXCR4 antagonists were shown to protect the
BBB and reduce inflammatory responses within the CNS [38]. Whereas the exact interactions between
CXCR4 and the BBB are yet to be determined, previous studies suggest a negative impact of CXCR4
on tight junction (TJ) proteins responsible for maintaining barrier function [38]. The CXCR4 mRNA
increase in HBMEC exposed to Ureaplasma spp. may therefore be an indicator of Ureaplasma-driven
impairment of TJ proteins via CXCR4 engagement, ultimately resulting in compromised BBB integrity.
This may be even more pronounced in the event of co-infections, as indicated by further amplified
CXCR4 mRNA responses in HBMEC co-stimulated with Ureaplasma spp. and LPS (Figure 3c,d, Table 1).
We recently demonstrated atypical chemokine receptor 3 induction in HBMEC exposed to
Ureaplasma spp. [26]. This receptor, formerly known as CXCR7, may also facilitate BBB breakdown [26].
Moreover, Ureaplasma-induced apoptosis in HBMEC may further impair barrier properties [25]. We
previously revealed reduced adhesion properties in Ureaplasma-exposed HBMEC [25]. BBB disruption
therefore appears to be of particular relevance in Ureaplasma-driven neuroinflammation. The BBB
usually provides both an anatomical barrier and a cytokine-dependent immunological control to
regulate passage into the CNS [24]. Compromised integrity of the BBB is considered a key factor in
neuroinflammation [23,39]. BBB impairment by Ureaplasma spp. may ultimately allow inflammatory
cell influx into the CNS but also facilitate pathogen entry into the brain. The resulting consequence
may be long-term intracerebral inflammation. This is particularly relevant when considering not only
cases describing chronic Ureaplasma meningitis but also those studies suggesting an association of
Ureaplasma spp. with IVH and cerebral palsy in preterm neonates, both conditions being promoted by
inflammation [5,11,12,19,20,40].
Taking together the exaggerated CXCR4 responses in co-stimulated cells and the Ureaplasma-driven
mitigation of LPS-induced cytokine and chemokine responses, Ureaplasma spp. appear to exert an
immunomodulatory capacity in the event of co-infection. This may be even more pronounced in the
event of non-simultaneous inflammatory hits [30] as occurring, for example, in chorioamnionitis. The
augmentation of some effects evoked by secondary impact factors and the attenuation of others may
both impair important CNS immune defense mechanisms just in those cells intended to protect the
brain. This immunomodulation may represent a key feature of the initiation of Ureaplasma-driven
neuroinflammation, ultimately facilitating invasive infection and consecutive tissue inflammation
even in the absence of “direct” Ureaplasma-evoked pro-inflammatory cytokine and chemokine effects.
Considering the frequency of co-infections and polymicrobial colonization in preterm infants, this
finding may be of particular relevance.
We did not detect any relevant basal or stimulation-induced anti-inflammatory IL-10 or IL-1RA
responses in HBMEC. This is in line with previous studies describing no LPS-induced IL-10 production
in brain endothelial cells [41]. Interestingly, IL-10 is considered protective against apoptosis by some
authors [42], and the lack thereof in HBMEC may indicate a particular vulnerability to apoptosis,
underlining our previous results [25] and ultimately again impairing BBB integrity.
The mechanisms behind Ureaplasma-driven immune modulation are not yet fully understood.
However, Ureaplasma spp. are known to employ Toll-like receptor (TLR) signaling [43,44]. Given
that TLR activate signaling pathways which induce numerous immune mediators, including
inflammatory cytokines [45], TLR engagement may be responsible for Ureaplasma-induced cytokine
and chemokine effects.
The Ureaplasma-driven effects observed in this study became obvious only after longer stimulation
periods (Figures 1–3), whereas LPS evoked earlier responses (Figure 1). This may be in line with
often subtle, subclinical Ureaplasma infections, which become relevant over the course of time rather
than as an acute infection. Case reports describe chronic Ureaplasma meningitis persisting for several
months [11,12].
This is the first study addressing Ureaplasma-driven cytokine and chemokine responses in
HBMEC. The study is strengthened by the use of two viable Ureaplasma isolates. Although subtle
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differences between Uu8 and Up3 were apparent regarding IL-8 and CXCR4 mRNA responses in
co-stimulated HBMEC (Figure 2m,n, Figure 3c,d), the isolates did not evoke distinctly diverging effects.
Another strength is the assessment of cytokine and chemokine responses at the level of mRNA and
protein expression.
In vitro studies can only partially resemble in vivo conditions, where external influencing factors
and complex interactions have to be taken into account. Furthermore, given the particular vulnerability
of preterm and term neonates, the use of an adult cell line may be considered a potential limitation of
this study. Therefore, future studies ought to be based on neonatal rather than adult cells and should
comprise tissue models or co-culture systems more closely resembling the complex in vivo BBB.
The findings presented in this study partially differ from results obtained previously, in which
our group demonstrated Ureaplasma-induced pro-inflammatory cytokine and chemokine responses in
primary human neonatal and adult monocytes but also a modulation of LPS-evoked effects [46,47].
Ureaplasma spp. therefore appear to exert tissue-specific pro- and anti-inflammatory effects, both
potentially with severe negative ramifications. Either way, our consistent in vitro findings of
Ureaplasma-driven immune modulation underline their pathogenicity and profound clinical relevance.
4. Materials and Methods
4.1. Bacterial Strains and Culture Conditions
Serovar 8 of U. urealyticum (Uu8) and serovar 3 of U. parvum (Up3) were acquired from the
American Tissue Culture Collection (ATCC; Uu8: ATCC 27618, Up3: ATCC 27815). Isolates were
propagated in a liquid in-house medium (“broth”) containing 82% autoclaved pleuropneumonia-like
organism medium (Becton, Dickinson & Company, Franklin Lakes, NJ, USA), 10% heat-inactivated
horse serum (v/v), 1% urea (w/v), and 0.002% phenol red (w/v) (all: Sigma-Aldrich, St. Louis, CA,
USA). The medium was passed through a 0.2 µm filter membrane (Sartorius, Goettingen, Germany)
and adjusted to pH 6.5. An endotoxin level of <0.06 EU/mL was verified (ToxinSensor™ Endotoxin
Detection System, GenScript, Piscataway, NJ, USA).
As described previously [26], 10-fold serial dilutions of Ureaplasma cultures were incubated to
obtain 1 × 109–1 × 1010 color-changing units (CCU)/mL of viable organisms. The corresponding
Ureaplasma DNA amounted to 5 × 107–6 × 108 copies/mL (Institute of Medical Microbiology and
Hospital Hygiene, Duesseldorf, Germany). Bacterial viability was confirmed by simultaneous culture
on selective agar plates (Mycoplasma Ureaplasma agar, medco Diagnostika GmbH, Ottobrunn, Germany).
4.2. Cell Line and Culture Conditions
Non-immortalized adult HBMEC (ACBRI 376, Cell Systems, Kirkland, WA, USA) were grown
to confluence in gelatin (Serva Electrophoresis, Heidelberg, Germany) coated T-75 culture flasks
(Greiner Bio-One, Frickenhausen, Germany) in a humid atmosphere at 37 ◦C with 5% CO2. Cells were
propagated in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal calf serum (Thermo
Fisher Scientific, Waltham, MA, USA), 10% Nu-Serum (BD Biosciences, San Jose, CA, USA), 2 mM
L-glutamine, 1 mM sodium pyruvate, 1% minimum essential medium with non-essential amino acids
(all: Thermo Fisher), 5 U/mL heparin (Biochrom, Berlin, Germany), and 0.3% endothelial cell growth
supplement (Cell Systems). As described previously [26], confluent monolayers were expanded, and
recently thawed cells of passage 8 were used for all experiments. Previous experiments had confirmed
basic endothelial characteristics [26].
4.3. Stimulation Assays
HBMEC were seeded in gelatin-coated 6-well culture plates (Greiner Bio-One) at a density of
2 × 105 cells/well and grown to confluence for 48 h. Monolayers were washed, and 1 mL of fresh
growth medium was added per well. E. coli serotype 055:B5 LPS (Sigma-Aldrich) was applied to a
subgroup of HBMEC at a concentration of 100 ng/mL. As described previously [26], 250 µL broth
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harboring 1 × 109–1 × 1010 CCU of Ureaplasma isolates was added per mL of HBMEC medium to native
or LPS co-stimulated HBMEC. Cultures were incubated for 4 and 30 h for mRNA analysis, whereas
incubation periods of 24 and 48 h were chosen for flow cytometry and multi-analyte immunoassay. The
doses and durations of stimulation were determined in previous experiments [26]. To acknowledge
potentially confounding broth effects, cells exposed to the broth control and unstimulated HBMEC
served as negative controls.
4.4. RNA Extraction and Reverse Transcriptase PCR (RT-PCR)
Total RNA was extracted using a NucleoSpin® RNA Kit (Macherey-Nagel, Dueren, Germany),
eluted in 60 µL RNAse-free H2O (Macherey-Nagel), quantified using a Qubit® 2.0 Fluorometer (Thermo
Fisher), and stored at −80 ◦C until reverse transcription. RT-PCR was performed with 1 µg of total
RNA using a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher). First-strand cDNA was
diluted 1:10 with nuclease-free H2O (Sigma-Aldrich) and stored at −20 ◦C until analysis.
4.5. Quantitative Real-Time RT-PCR (qRT-PCR)
For quantitative detection of mRNA, cDNA was analyzed in duplicates of 25 µL reaction mixture
containing 12.5 µL iTaq™ Universal SYBR® Green Supermix (Bio-Rad Laboratories, Hercules, CA,
USA), 0.5 µL nuclease-free H2O, and 1 µL of a 10 µM solution of forward and reverse primers
(Sigma-Aldrich) as indicated in Table 2. Analysis was performed using an Applied Biosystems® 7500
Real-Time PCR System (Thermo Fisher) with a two-step PCR protocol including an initial denaturation
at 95 ◦C for 10 min and 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. At the end of every run, melt
curve analysis was used to verify single PCR products. Amplification was normalized to the reference
gene hypoxanthine phosphoribosyltransferase (HPRT) 1 and mean fold changes in mRNA expression
were calculated according to the ∆∆CT method [48]. Experiments were repeated five times (n = 5).
Table 2. Primers used for qRT-PCR.
Name Gene Symbol SequenceAccession No. Orientation Sequence [5
′ to 3′]
CXCL5 CXCL5 NM_002994.5
forward GTTGCGTTTGTTTACAGACC
reverse TTTCCTTGTTTCCACCGT
CXCR4 CXCR4 NM_001008540.2
forward AAGACCACAGTCATCCTC
reverse GTTCTCAAACTCACACCCT
HPRT1 HPRT1 NM_000194.2
forward CTGGCGTCGTGATTAGTG
reverse AGTCCTGTCCATAATTAGTCC
IL-1α IL1α NM_000575.4
forward ATGGATCAATCTGTGTCTCTG
reverse GCTTGATGATTTCTTCCTCTG
IL-1β IL1β NM_000576.2
forward TTCATTGCTCAAGTGTCTG
reverse GCACTTCATCTGTTTAGGG
IL-8 IL8 NM_000584.4
forward CAGTGCATAAAGACATACTCC
reverse TTTATGAATTCTCAGCCCTC
IL-10 IL10 NM_000572.3
forward GCTGTCATCGATTTCTTCC
reverse GTCAAACTCACTCATGGCT
MCP-1 CCL2 NM_002982.4
forward GCTGTGATCTTCAAGACC
reverse AAGTCTTCGGAGTTTGGG
MCP-3 CCL7 NM_006273.3
forward CTGAGACCAAACCAGAAACC
reverse TATTAATCCCAACTGGCTGAG
MMP-9 MMP9 NM_004994.3
forward GGATGGGAAGTACTGGCGA
reverse CTCCTCAAAGACCGAGTCC
TNF-α TNFα NM_000594.4
forward CAGCCTCTTCTCCTTCCT
reverse GGGTTTGCTACAACATGG
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4.6. RNA Sequencing
Total RNA was extracted using a NucleoSpin® RNA Kit (Macherey-Nagel), and samples were
stored at −80 ◦C until further processing. Experiments were repeated three times (n = 3). Libraries
were prepared at the Core Unit Systems Medicine, University of Wuerzburg, Germany, using the
Illumina TruSeq stranded mRNA Kit (Illumina, San Diego, CA, USA) with 700 ng of input RNA
and 13 PCR cycles. Thirteen or fourteen libraries were pooled and sequenced on a NextSeq 500
(Illumina) with a read length of 75 nucleotides, producing about 34–40 million raw reads per library.
The Illumina TruSeq adaptors were cleaved with the help of cutadapt (version 1.14) [49], and reads were
trimmed keeping the quality drop value below a mean of Q20. FastQC 0.11.5 (Braham bioinformatics,
Cambridge, UK) [50] was used for assessing the read quality, number of duplicates, and presence of
adapter sequences. Processed sequences were mapped to the human genome by employing the short
read aligner STAR (version 2.5.2b) [51] with genome and annotation files from GENCODE (version
25—March 2016 freeze, GRCh38). For all samples, the proportion of reads mapped to the human
reference genome ranged between 76% and 90% in total. Sequences aligning to specific genes were
quantified using the bedtools subcommand intersect (version 2.15.0) [52], and differentially expressed
genes were identified with the help of DESeq2 (version 1.16.1) [53]. The significance threshold for
Benjamini–Hochberg corrected p-values was set at 0.05. To compare different groups, reads per kilo
base per million mapped reads (RPKM) were calculated for individual genes using DGEList and the
RPKM function from edgeR [54].
4.7. Multi-Analyte Immunoassay
Following stimulation, supernatants were collected and stored at −80 ◦C until analysis. Using
Luminex® multiplex kits and xPonent® software (Merck group, Darmstadt, Germany), concentrations
of secreted proteins were determined with the help of a standard curve. The lower detection limits
were 11.0 pg/mL (CXCL5), 0.6 pg/mL (IL-1α), 0,9 pg/mL (IL-1β), 6.3 pg/mL (IL-1RA), 2.5 pg/mL (IL-6),
1.8 pg/mL (IL-8), 1.8 pg/mL (IL-10), 2.2 pg/mL (MCP-1), 5.0 pg/mL (MCP-3), 16.7 pg/mL (MMP-9), and
0.49 pg/mL (TNF-α), and values underneath were set to 0. Samples were analyzed in duplicate, and
experiments were repeated five times (n = 5).
4.8. Flow Cytometry
For Fc-receptor blocking, harvested cells were incubated with gamunex (Grifols, Frankfurt,
Germany) at a concentration of 4 mg/mL. Cells were separated by centrifugation and stained with
a Brilliant Violet conjugated antibody to cluster of differentiation (CD) 31 (BV 510, BD Biosciences),
a PerCP conjugated antibody to MMP-9 (Assay Pro, St. Charles, MO, USA), and Fixable Viability
Dye eFluorTM 780 (eBioScience, Thermo Fisher), a dye labelling dead cells. After centrifugation,
cells were resuspended in phosphate-buffered saline (PBS, Sigma-Aldrich) containing 1% human
serum (HS, Biochrom GmbH), fixed using fixation buffer (BioLegend, San Diego, CA, USA), and
permeabilized in permeabilization wash buffer (BioLegend). Cells were then stained with antibodies
to IL-8 (Alexa Fluor 488 conjugated, BioLegend) and IL-10 (APC conjugated, BioLegend). After
centrifugation and resuspension in PBS/HS, samples were read on a FACSCanto™ II flow cytometer
(BD Biosciences). A minimum of 10,000 events was acquired to be analyzed with FACSDiva v6.1.3
software (BD Biosciences). A side scatter height versus forward scatter width dot plot was used to
exclude doublets, and cells were gated for viable, CD31-positive events. Experiments were repeated at
least five times (n ≥ 5).
4.9. Statistical Analysis
Results were analyzed with the help of Prism® 6 software (GraphPad Software, San Diego, CA,
USA), using a one-way ANOVA with Tukey’s multiple comparisons test. Results with a corrected
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p-value of <0.05 were considered as significantly differentially expressed. Data are shown as means ±
standard deviation (SD).
5. Conclusions
In marked contrast to other pathogens, Ureaplasma spp. rarely cause fierce CNS infections but
rather induce subtle, long-term neuroinflammation. For the first time, our results convey insights into
underlying cytokine and chemokine coherences. This in vitro study does not provide evidence for
“classic” Ureaplasma-driven pro-inflammation in HBMEC but rather suggests an immunomodulatory
capacity of Ureaplasma spp. in co-infections in vivo. Particularly in the presence of a secondary
impact factor, Ureaplasma spp. may (i) mitigate pro-inflammatory cytokine and chemokine responses,
impeding effective immune defense and allowing pathogen persistence; (ii) hamper neuro-protective
mechanisms, increasing CNS vulnerability; and (iii) compromise BBB integrity, allowing pathogen and
inflammatory cell influx into the CNS. All of these effects may ultimately facilitate invasive infections,
chronic colonization, long-term neuroinflammation, and subsequent brain injury. Ureaplasma spp.
therefore have to be considered relevant pathogens in neonatal neuroinflammation, particularly in the
event of co-infection.
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IL interleukin
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MCP monocyte chemoattractant protein
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qRT-PCR quantitative real-time reverse transcriptase polymerase chain reaction
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